Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes

Breast cancer (BC) is a heterogeneous disease, which is primarily classified according to hormone receptors and HER2 expression. Despite the many advances in BC diagnosis and management, the identification of novel actionable therapeutic targets expressed by cancerous cells has always been a dauntin...

Full description

Bibliographic Details
Main Authors: Radhakrishnan Vishnubalaji, Nehad M. Alajez
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/12/8/1182
_version_ 1797605996127846400
author Radhakrishnan Vishnubalaji
Nehad M. Alajez
author_facet Radhakrishnan Vishnubalaji
Nehad M. Alajez
author_sort Radhakrishnan Vishnubalaji
collection DOAJ
description Breast cancer (BC) is a heterogeneous disease, which is primarily classified according to hormone receptors and HER2 expression. Despite the many advances in BC diagnosis and management, the identification of novel actionable therapeutic targets expressed by cancerous cells has always been a daunting task due to the large heterogeneity of the disease and the presence of non-cancerous cells (i.e., immune cells and stromal cells) within the tumor microenvironment. In the current study, we employed computational algorithms to decipher the cellular composition of estrogen receptor-positive (ER<sup>+</sup>), HER2<sup>+</sup>, ER<sup>+</sup>HER2<sup>+</sup>, and triple-negative BC (TNBC) subtypes from a total of 49,899 single cells’ publicly available transcriptomic data derived from 26 BC patients. Restricting the analysis to EPCAM<sup>+</sup>Lin<sup>−</sup> tumor epithelial cells, we identified the enriched gene sets in each BC molecular subtype. Integration of single-cell transcriptomic with CRISPR-Cas9 functional screen data identified 13 potential therapeutic targets for ER<sup>+</sup>, 44 potential therapeutic targets for HER2<sup>+</sup>, and 29 potential therapeutic targets for TNBC. Interestingly, several of the identified therapeutic targets outperformed the current standard of care for each BC subtype. Given the aggressive nature and lack of targeted therapies for TNBC, elevated expression of ENO1, FDPS, CCT6A, TUBB2A, and PGK1 predicted worse relapse-free survival (RFS) in basal BC (<i>n</i> = 442), while elevated expression of ENO1, FDPS, CCT6A, and PGK1 was observed in the most aggressive BLIS TNBC subtype. Mechanistically, targeted depletion of ENO1 and FDPS halted TNBC cell proliferation, colony formation, and organoid tumor growth under 3-dimensional conditions and increased cell death, suggesting their potential use as novel therapeutic targets for TNBC. Differential expression and gene set enrichment analysis in TNBC revealed enrichment in the cycle and mitosis functional categories in FDPS<sup>high</sup>, while ENO1<sup>high</sup> was associated with numerous functional categories, including cell cycle, glycolysis, and ATP metabolic processes. Taken together, our data are the first to unravel the unique gene signatures and to identify novel dependencies and therapeutic vulnerabilities for each BC molecular subtype, thus setting the foundation for the future development of more effective targeted therapies for BC.
first_indexed 2024-03-11T05:09:06Z
format Article
id doaj.art-6d003194aca34284a2cdbdcc40ad851e
institution Directory Open Access Journal
issn 2073-4409
language English
last_indexed 2024-03-11T05:09:06Z
publishDate 2023-04-01
publisher MDPI AG
record_format Article
series Cells
spelling doaj.art-6d003194aca34284a2cdbdcc40ad851e2023-11-17T18:43:39ZengMDPI AGCells2073-44092023-04-01128118210.3390/cells12081182Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer SubtypesRadhakrishnan Vishnubalaji0Nehad M. Alajez1Translational Cancer and Immunity Center (TCIC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha P.O. Box 34110, QatarTranslational Cancer and Immunity Center (TCIC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha P.O. Box 34110, QatarBreast cancer (BC) is a heterogeneous disease, which is primarily classified according to hormone receptors and HER2 expression. Despite the many advances in BC diagnosis and management, the identification of novel actionable therapeutic targets expressed by cancerous cells has always been a daunting task due to the large heterogeneity of the disease and the presence of non-cancerous cells (i.e., immune cells and stromal cells) within the tumor microenvironment. In the current study, we employed computational algorithms to decipher the cellular composition of estrogen receptor-positive (ER<sup>+</sup>), HER2<sup>+</sup>, ER<sup>+</sup>HER2<sup>+</sup>, and triple-negative BC (TNBC) subtypes from a total of 49,899 single cells’ publicly available transcriptomic data derived from 26 BC patients. Restricting the analysis to EPCAM<sup>+</sup>Lin<sup>−</sup> tumor epithelial cells, we identified the enriched gene sets in each BC molecular subtype. Integration of single-cell transcriptomic with CRISPR-Cas9 functional screen data identified 13 potential therapeutic targets for ER<sup>+</sup>, 44 potential therapeutic targets for HER2<sup>+</sup>, and 29 potential therapeutic targets for TNBC. Interestingly, several of the identified therapeutic targets outperformed the current standard of care for each BC subtype. Given the aggressive nature and lack of targeted therapies for TNBC, elevated expression of ENO1, FDPS, CCT6A, TUBB2A, and PGK1 predicted worse relapse-free survival (RFS) in basal BC (<i>n</i> = 442), while elevated expression of ENO1, FDPS, CCT6A, and PGK1 was observed in the most aggressive BLIS TNBC subtype. Mechanistically, targeted depletion of ENO1 and FDPS halted TNBC cell proliferation, colony formation, and organoid tumor growth under 3-dimensional conditions and increased cell death, suggesting their potential use as novel therapeutic targets for TNBC. Differential expression and gene set enrichment analysis in TNBC revealed enrichment in the cycle and mitosis functional categories in FDPS<sup>high</sup>, while ENO1<sup>high</sup> was associated with numerous functional categories, including cell cycle, glycolysis, and ATP metabolic processes. Taken together, our data are the first to unravel the unique gene signatures and to identify novel dependencies and therapeutic vulnerabilities for each BC molecular subtype, thus setting the foundation for the future development of more effective targeted therapies for BC.https://www.mdpi.com/2073-4409/12/8/1182single cell analysisbreast cancermolecular subtypesTNBCtherapeutic targets
spellingShingle Radhakrishnan Vishnubalaji
Nehad M. Alajez
Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes
Cells
single cell analysis
breast cancer
molecular subtypes
TNBC
therapeutic targets
title Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes
title_full Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes
title_fullStr Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes
title_full_unstemmed Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes
title_short Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes
title_sort single cell transcriptome analysis revealed heterogeneity and identified novel therapeutic targets for breast cancer subtypes
topic single cell analysis
breast cancer
molecular subtypes
TNBC
therapeutic targets
url https://www.mdpi.com/2073-4409/12/8/1182
work_keys_str_mv AT radhakrishnanvishnubalaji singlecelltranscriptomeanalysisrevealedheterogeneityandidentifiednoveltherapeutictargetsforbreastcancersubtypes
AT nehadmalajez singlecelltranscriptomeanalysisrevealedheterogeneityandidentifiednoveltherapeutictargetsforbreastcancersubtypes